NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

Clinical trial NCT06081244 · RECRUITING

Trial details

NCT number: NCT06081244
Sponsor: Women's Cancer Study Group GmbH
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Triple Negative Breast Cancer

Start date: 2024-10-10
Primary completion: 2029-09-01
Enrollment: 348

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.